| scholarly article | Q13442814 |
| P50 | author | Ann S LaCasce | Q89672650 |
| P2093 | author name string | Jennifer L Crombie | |
| P2860 | cites work | Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines | Q26745838 |
| Epstein-Barr virus latent genes | Q28082701 | ||
| An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. | Q52317335 | ||
| Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? | Q57170541 | ||
| Gene Expression Profiling Reveals Clear Differences Between EBV-Positive and EBV-Negative Posttransplant Lymphoproliferative Disorders | Q58063835 | ||
| How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa | Q62490169 | ||
| Pretransplantation assessment of the risk of lymphoproliferative disorder | Q71910946 | ||
| Lymphomas after solid organ transplantation: a collaborative transplant study report | Q76376056 | ||
| Post-transplant lymphoproliferative disorders | Q79775030 | ||
| Targeting oncogenic Myc as a strategy for cancer treatment | Q88021277 | ||
| Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation | Q90397575 | ||
| Immunosenescence: deficits in adaptive immunity in the elderly | Q28238448 | ||
| Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules | Q30313852 | ||
| Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation | Q33183745 | ||
| Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia | Q33330621 | ||
| Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen | Q33495648 | ||
| Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries | Q33583294 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. | Q33710720 | ||
| Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis | Q33732489 | ||
| Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept | Q33806671 | ||
| VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA | Q33971399 | ||
| Burkitt's lymphoma: clinicopathologic features and differential diagnosis | Q33995055 | ||
| Burkitt's lymphoma | Q34030708 | ||
| An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study | Q34526281 | ||
| Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. | Q34546619 | ||
| Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia | Q34565132 | ||
| Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial | Q34623991 | ||
| Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis | Q34627112 | ||
| Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). | Q34815054 | ||
| EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management | Q35040644 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. | Q35629356 | ||
| Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies | Q35829978 | ||
| Spectrum of cancer risk among US solid organ transplant recipients | Q35848186 | ||
| Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) | Q35849039 | ||
| Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy | Q35875897 | ||
| EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. | Q35953524 | ||
| A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). | Q36868708 | ||
| The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Q36920426 | ||
| EBV-associated lymphoproliferative disorders: classification and treatment | Q37178820 | ||
| Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation | Q37201899 | ||
| Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas | Q37280924 | ||
| Low-intensity therapy in adults with Burkitt's lymphoma. | Q37511989 | ||
| Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation | Q37552052 | ||
| Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. | Q37718297 | ||
| Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. | Q37735259 | ||
| Lymphoma: risk and response after solid organ transplant. | Q37817421 | ||
| The pathogenesis of Epstein-Barr virus persistent infection. | Q38107595 | ||
| Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies | Q38112050 | ||
| Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. | Q38383351 | ||
| Immune checkpoint blockade in hematologic malignancies | Q38400922 | ||
| How I treat posttransplant lymphoproliferative disorders | Q38589013 | ||
| The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma | Q38596354 | ||
| EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management | Q38812004 | ||
| The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review | Q38933152 | ||
| Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey | Q39427348 | ||
| Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. | Q39464615 | ||
| Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders | Q39596345 | ||
| Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin | Q40547410 | ||
| The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder | Q41219311 | ||
| EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? | Q41617875 | ||
| How I treat Burkitt lymphoma in adults | Q41725426 | ||
| Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. | Q42628866 | ||
| Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. | Q42630638 | ||
| Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis | Q42958226 | ||
| Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms | Q43972946 | ||
| Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab | Q44150295 | ||
| Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. | Q44891160 | ||
| Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity | Q44908722 | ||
| Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients | Q44943282 | ||
| Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression | Q45351817 | ||
| Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients | Q45360184 | ||
| The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma | Q45405661 | ||
| Validation of prognostic scores in post-transplantation lymphoproliferative disorders | Q45790732 | ||
| Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. | Q46722604 | ||
| Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression | Q46825318 | ||
| Post-Transplantation Lymphoproliferative Disorders in Adults | Q50135767 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphoproliferative disorders | Q4165484 |
| PTLD | Q7120981 | ||
| P304 | page(s) | 109 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders | |
| P478 | volume | 9 |
| Q95841150 | Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact |
| Q90012597 | Epstein barr virus encodes miRNAs to assist host immune escape |
| Q90286897 | Metagenomic Next-Generation Sequencing for Identification and Quantitation of Transplant-Related DNA Viruses |
| Q95577490 | Multiple Brain Biopsies for Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma with Extensive Necrosis in a Posttransplant Patient |
| Q92006909 | Novel replisome-associated proteins at cellular replication forks in EBV-transformed B lymphocytes |
Search more.